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Abstract
Background: The use of Fall-Risk-Increasing-Drugs (FRIDs) has been associated with increased risk of falls and
associated injuries. This study investigates the effect of withdrawal of FRIDs versus ‘care as usual’ on health-related
quality of life (HRQoL), costs, and cost-utility in community-dwelling older fallers.
Methods: In a prospective multicenter randomized controlled trial FRIDs assessment combined with FRIDs-withdrawal
or modification was compared with ‘care as usual’ in older persons, who visited the emergency department after
experiencing a fall. For the calculation of costs the direct medical costs (intramural and extramural) and indirect costs
(travel costs) were collected for a 12 month period. HRQoL was measured at baseline and at 12 months follow-up using
the EuroQol-5D and Short Form-12 version 2. The change in EuroQol-5D and Short Form-12 scores over 12 months
follow-up within the control and intervention groups was compared using the Wilcoxon Signed Rank test for continuous
variables and the McNemar test for dichotomous variables. The change in scores between the control and intervention
groups were compared using a two-way analysis of variance.
Results: We included 612 older persons who visited an emergency department because of a fall. The mean cost of the
FRIDs intervention was €120 per patient. The total fall-related healthcare costs (without the intervention costs) did not
differ significantly between the intervention group and the control group (€2204 versus €2285). However, the withdrawal
of FRIDs reduced medication costs with a mean of €38 per participant. Furthermore, the control group had a greater
decline in EuroQol-5D utility score during the 12-months follow-up than the intervention group (p = 0.02). The change in
the Short Form-12 Physical Component Summary and Mental Component Summary scores did not differ significantly
between the two groups.
Conclusions: Withdrawal of FRID’s in older persons who visited an emergency department due to a fall, did not lead to
reduction of total health-care costs. However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per
participant in combination with less decline in HRQoL is an important result.
Trial registration: The trial is registered in the Netherlands Trial Register (NTR1593 – October 1st 2008).
Keywords: Quality of life, Medication withdrawal, Cost utility, Older persons, Falls
* Correspondence: s.polinder@erasmusmc.nl
1Department of Public Health, Erasmus MC, University Medical Center
Rotterdam, PO Box 20403000, CA, Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Polinder et al. BMC Geriatrics  (2016) 16:179 
DOI 10.1186/s12877-016-0354-7
Background
Fall incidents represent an increasing burden on health
care systems in aging societies worldwide. Falls affect a
large proportion of persons aged 65 years and older and
are associated with high mortality and morbidity, leading
to great personal suffering, represented in loss of quality
of life and high costs [1–5]. Older fallers cause high
numbers of Emergency Department (ED) visits and
hospital admissions [6, 7]. In 2000, the fall-related
medical costs in the population aged 65 years and older
in the United States amounted to US$19 billion for non-
fatal injuries and US$200 million for fatal injuries [8].
Between 2003 and 2007 the average annual cost for fall-
related injuries in the Netherlands was US$640 million
(€470 million) [9]. The overall cost per fall was
US$10,540 (€7800), mainly caused by direct medical
costs [10].
In order to reduce the prevalence of falls, potentially
avoidable risk factors have been well documented [11–13],
and there has been a substantial number of falls preven-
tion trials [5, 14–22]. However, past variations in outcome
definitions and measures of falls prevention trials have
hindered comparative research and meta-analysis, and
thus the Prevention of Falls Network Europe (ProFaNE)
established a common set of outcome definitions and
measures for use in trials. These include costs, health-
related quality of life (HRQoL) outcomes, and a follow-up
duration of 12 months [23]. But so far only few fall-
prevention trials have documented quality of life out-
comes [18, 24–27] and the HRQoL as recommended by
ProFaNE has been reported in only one of them [18].
Moreover, economic evaluations on falls prevention are
scarce. However, evidence from reviews targeting
economic evaluation studies of single factor falls prevention
interventions like exercise programs [28, 29] and multifac-
torial falls prevention interventions [30] is promising.
The use of FRIDs has been associated with increased risk
of falls and associated injuries [31–35]. The withdrawal of
FRIDs has been shown to be safely possible and to generate
significant cost savings in some patients [14, 36, 37], but
the cost-utility of this approach has not been reported yet.
The present study investigated costs, the effect on HRQoL,
and the cost-utility of a structured medication assessment
including withdrawal of FRIDs versus ‘care as usual’ in
community-dwelling older men and women, who visited
the ED after experiencing a fall [38].
Methods
Study design
The IMPROveFALL study is a multicenter random-
ized controlled trial in the Netherlands. Eligible
patients were randomized to one of the treatment
arms using a web-based randomization program. Vari-
able block randomization was accomplished via a trial
website. Allocation was at random and concealed.
The patients were randomized to the intervention
group or ‘care as usual’. It was not possible to blind
the geriatrician and patients for the allocation of the
study group. The study was performed in accordance
with the Declaration of Helsinki and all participants
gave written informed consent. The local Medical
Research Ethics Committees in the six participating
hospitals approved the study protocol. A detailed
description of the study protocol can be found
elsewhere [38].
Study population
Patients meeting the following inclusion criteria were eli-
gible for enrolment: age 65 years or older, visited the ED
due to a fall, use of one or more FRIDs [32, 33, 35, 38],
Mini-Mental State Examination (MMSE) score of at least
21 out of 30 points [39], ability to walk independently,
community dwelling, and provision of written informed
consent by the patient. Participating hospitals included
two academic and four regional hospitals in the
Netherlands. Enrolment started in October 2008 and was
completed in October 2011. The follow-up period was
12 months.
All persons visiting the ED because of a fall received
care as usual for their injuries. Following the ED visit,
patients were contacted by telephone. Subsequently,
eligible and interested potential study participants
received an appointment for the research outpatient
clinic. The visits to the research outpatient clinic took
place within two months after the fall-related ED visit. If
the patient met all eligibility criteria, the patient was
asked to sign the Informed Consent form. During the
visit to the research outpatient clinic, a fall-related
assessment was performed by the research physician.
Intervention
All participants received a structured medication assess-
ment. The intervention group consisted of a systematic
FRIDs assessment combined with FRIDs withdrawal or
modification, if safely possible. A complete list of FRIDs
is presented in Appendix A. For each drug, the research
physician assessed whether the initial indication still
existed. Proposed changes in medication were discussed
with a senior geriatrician, and if necessary with the pre-
scribing physician. A research nurse offered counselling,
evaluated possible negative effects via a standardized
telephone follow-up, and discussed any problems regard-
ing the drug modification with the research physician
and geriatrician.
Definition fall incident
A fall was defined as coming to rest unintentionally on
the ground or a lower level with or without losing
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consciousness, but not induced by acute medical condi-
tions, e.g., stroke, or exogenous factors such as a traffic
accident [40]. All participants received a Falls Calendar
for reporting falls during a one-year follow-up period.
Falls were recorded weekly on the Fall Calendars, which
had to be returned every three months. Follow-up
started two weeks after completed intervention or two
weeks after initial research clinic visit when no interven-
tion was performed.
Costs
The total direct and indirect costs of both FRIDs with-
drawal and ‘care as usual’ were measured. Costs were
calculated by multiplying the volumes of healthcare use
with the corresponding unit prices (Table 1). Direct
healthcare costs included the costs of the FRIDs assess-
ment and modification, drug consumption (i.e., the cost
of substitution drugs), and fall-related healthcare con-
sumption during one year of follow-up (e.g., outpatient
visits, hospital admissions, General Practitioner consul-
tations, home care, nursing home care). Indirect costs
included patient travel costs. For the intervention (sys-
tematic fall-related drugs assessment) the full cost price
was calculated and for the other healthcare costs stand-
ard Dutch cost prices were used as published earlier by
Hakkaart-van Roijen et al. [41]. Costs of medication use
were recorded in the study, and unit costs were deter-
mined with information from the National Dutch
Formulary [42]. Healthcare consumption, both fall and
non-fall related, and patient costs were recorded from the
three-monthly questionnaires for healthcare consumption
and patient costs. Furthermore we collected data from the
participants’ General Practitioner, by sending a question-
naire on healthcare use.
The number of injuries prevented was calculated with
data recorded in the three-monthly questionnaire, sup-
plemented with epidemiological data on falls and injury
risks. These were supplemented with data on healthcare
costs of injury from previous research [10].
Health-related quality of life
During the baseline assessment and during the follow-
up visit at 12 months follow-up, all participants were
asked to complete the patient outcome questionnaire
(see Additional file 1), under supervision of the clinical
investigator or research nurse. Based upon the recom-
mendations of ProFaNE [23], HRQoL was measured
using the Dutch versions of the EuroQol-5D (EQ-5D)
[43] and the Short Form-12 (SF-12) version 2 [44]. The
EQ-5D is recommended for the assessment of HRQoL
in trauma patients, especially for economic assessments
[45]. The EQ-5D instrument covers five health domains
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression). Each dimension has three levels; no
problem, moderate problem, or severe problem. In
addition, a scoring algorithm based on empiric valua-
tions from the United Kingdom general population and
subsequent statistical modeling is available by which the
health status descriptions can be expressed into a utility
score [46]. This utility score ranges from 1 for full health
to 0 for death, and can be interpreted as a judgment on
the relative desirability of a health status compared with
perfect health. The EQ-5D is a validated and extensively
used general health questionnaire to measure quality of
life [43]. The SF-12 contains eight domains measuring
physical and mental health outcomes; physical function-
ing, role physical, bodily pain, general health, vitality,
social functioning, role emotional, and mental health.
Data from all eight domains are used to construct the
physical and mental component summary measures
(PCS and MCS) [44].
Cost-utility analysis
The long-term effectiveness of the interventions was
expressed in terms of the cumulative number of life
years and quality-adjusted life years (QALYs) gained.
The QALY combines morbidity and mortality into a
single number. QALYs were calculated by weighting life
years for the quality of life using the EQ-5D utility score
over 12 months (12 months follow-up minus baseline).
The gain in QALY is equal to the difference of QALY
outcomes between the two study arms.
Finally, the cost per QALY gained was calculated as
the ratio of total intervention costs minus savings in fall-
related healthcare costs compared with control divided
Table 1 List of costs
Cost categories Parameter Source of
consumption data
Cost price
(€, 2009)
Intervention costs * Study registry Variable
Medication costs DDD Study registry Variable
Hospital stay costs Day Hospital registry 457
Emergency Department
costs
Visit Hospital registry 151
General Practitioner costs Consultation Questionnaire 28
Specialist consult costs Consultation Hospital registry 72
Home care costs Per hour Questionnaire 35
Physical therapy costs Visit Questionnaire 36
Nursing home costs Day Questionnaire 238
Intermediate care facility
costs
Day Questionnaire 90
Rehabilitation center
costs
Day Questionnaire 340
Patient costs (travel costs) Per kilometer Questionnaire Variable**
DDD Defined Daily Dose, GP General Practitioner
*Geratric consultation (€72) + routine blood test (€20) + extra consults (€72)
**Private motor vehicle/public transportation/taxi
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by the cumulative QALYs gained compared with control.
All analyses were performed in accordance with Dutch
guidelines for economic evaluations [47].
Statistical analyses
All analyses were performed using the Statistical Package
of the Social Sciences (SPSS version 17.0, Chicago, Ill.)
and a p-value < 0.05 was considered statistically signifi-
cant. Missing data were not imputed. Baseline character-
istics were compared using Student t-test analyses for
continuous variables and chi-squared analyses for
dichotomous variables. The change in EQ-5D utility
score and SF-12 PCS and MCS scores over 12 months
(i.e., after 12 months follow-up minus baseline data)
within the control and intervention groups were com-
pared using the Wilcoxon Signed Rank test for continu-
ous variables and the McNemar test for dichotomous
variables. The change in scores between the control and
intervention groups were compared using a two-way
analysis of variance (ANOVA). Analyses of the individual
health domains of the EQ-5D and SF-12 were also
performed. Secondary analyses were performed, compar-
ing the HRQoL scores of the participants with and
without a fall during follow-up.
Results
In total, 7081 ED visitors were screened for inclusion in
the study, of which 3294 were not eligible, 1954 refused
to participate, 279 persons died before contact, 938 pa-
tients were failed to contact within 2 months, and of 4
patients data was lost. Subsequently, 612 participants
were randomized in the IMPROveFALL study (Fig. 1).
This randomization resulted in 319 participants to the
intervention group and 293 participants allocated to the
control group. In total 271 participants from the control
group and 308 participants from the intervention group
had complete intramural and extramural cost informa-
tion. Finally, 265 and 287 participants respectively from
the control and intervention group completed quality of
life assessments at baseline and at 12 months follow-up
(Fig. 1). The mean age was 76 years and 62 % of the
study population was female. No significant differences
in baseline characteristics were found between the con-
trol and intervention group (Table 2).
The number of participants in the control group and
intervention group experiencing a fall or recurrent fall
during the one-year follow-up did not differ significantly
(34 % versus 37 %; p = 0.33) [48].
The mean number of FRIDs used at baseline was four.
In 40 % of all FRIDs an intervention was deemed not
possible or not necessary. Of all attempted FRID-
withdrawals 35 % failed, either due to non-compliance
or due to a return of the primary indication for which
the drug had initially been prescribed. More detailed
specifications on the interventions according to FRID
categories and specific drug types, and details on com-
pliance to attempted interventions has been published
before [48].
Intervention costs
The mean cost of the FRIDs intervention was €120 per
patient, which included the initial research clinic assess-
ment (€72), routine blood tests (€20) and when neces-
sary (78 patients one or more checks) additional checks/
assessments (€72).
Cost savings
The mean costs saved with medication withdrawal, dose
reduction and drug substitution was €38 per participant
for the intervention group.
For all other intramural and extramural care no sig-
nificant differences in costs were found, except for gen-
eral practitioner visits (Table 3). However, for all but two
health care items the costs were lower for the interven-
tion group. Rehabilitation caused relatively the highest
costs, with much higher costs for the intervention group
than for the control group (€708 versus €229; NS). In
total 15 patients received rehabilitation care (10 in the
intervention arm) varying from 6 to 120 days stay, of
which the 6 patients with the longest stay in rehabilita-
tion were all in the intervention arm. Comparing inter-
mediate care facility and nursing home costs between
both groups, it is striking that the numbers of patients
receiving either type of care were similar, however, the
long stayers for both health care facilities were in the
control group.
The intramural and extramural fall-related healthcare
costs (without the intervention costs of €120) did not
differ significantly between the intervention group com-
pared with the control group (€2204 versus €2285; NS).
Health-related quality of life
Nine participants in the control and 23 in the interven-
tion group declined or were unable to complete the EQ-
5D questionnaires after 12-months follow-up. Additional
5 and 2 participants in the control and intervention
group, respectively, had incomplete SF-12 questionnaires
after 12-months follow-up.
The baseline and follow-up HRQoL scores of the
control and intervention group are shown in Table 4.
The control group had a greater decline in EQ-5D utility
score during the 12-months follow-up than the interven-
tion group, (p = 0.02). The decline in the SF-12 PCS and
MCS score did not differ significantly between the two
groups (p = 0.08 and p = 0.90). The problems in the
EQ-5D domains of the control and intervention group
reported at baseline and at follow-up are shown in Fig. 2.
Control patients reported significantly more problems
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with mobility (increase of 9 %; p = 0.01) at 12-months
follow-up, which mainly explains the decline in HRQoL
in the control group.
The overall mean baseline EQ-5D utility score of par-
ticipants with and without a fall during follow-up was
0.69 ± 0.27 and 0.80 ± 0.21, respectively (p < 0.01). The
overall mean baseline SF-12 PCS scores of those with
and without a fall during follow-up were 44.4 ± 9.9, and
46.6 ± 9.6, p = 0.01. The overall mean baseline SF-12
MCS scores of those with and without a fall during
follow-up were 53.2 ± 10.0, and 53.3 ± 9.0, p = 0.87. Thus,
the participants who experienced further falls during
follow-up had significantly lower EQ-5D and SF-12 PCS
scores at baseline. A secondary analysis was performed
of the decline in HRQoL in the participants of the
control and intervention group with and without a fall
during follow-up (Table 5). In the participants with a fall
during follow-up, the change in quality of life did not
differ significantly between both groups. In the partici-
pants without a fall during follow-up, the control group
had a greater decline in the SF-12 PCS score (p = 0.01)
than the intervention group.
Cost-utility
The mean QALY difference between both groups was
0.05 QALY (gained by the intervention group) over the
trial period. For the total fall-related healthcare costs
(with and without the intervention costs of €120), no
significantly differences between both study groups
could be detected. Therefore, no incremental cost-utility
ratio was calculated.
Discussion
This is the first cost-utility analysis comparing a struc-
tured medication assessment including withdrawal of
FRIDs versus ‘care as usual’ in community-dwelling
Fig. 1 Flowchart of study participants. *Of the participants who died during follow-up, most were included in the analyses, except for two in the
control and one in the intervention group. **Nine and 23 participants in the control and intervention group declined or were unable to complete
EQ-5D questionnaires after 12-months follow-up
Polinder et al. BMC Geriatrics  (2016) 16:179 Page 5 of 10
older fallers conform the PROFANE guideline. The sav-
ings in fall-related healthcare cost did not differ signifi-
cantly between the control and intervention group.
However, the control group reported a significantly
greater decline in HRQoL during the 12-months follow-
up as measured with the EQ-5D utility score than the
intervention group.
Various studies have reported costs and cost-
effectiveness data regarding falls prevention trials with
varying results. But these studies evaluated, in most
cases, multifactorial interventions [30, 49–58]. One
study reported on the cost-effectiveness of FRIDs with-
drawal as a single intervention, and reported significant
national cost savings [36]. In the current study, the
savings in fall-related healthcare related costs in the
intervention group did not differ significantly from usual
care. This seems consistent with our findings that
FRIDs-withdrawal was not effective in reducing falls
[48]. There are several possible explanations for this lack
of fall incidence reduction. In short, since in the last
decade falls prevention guidelines have been incorpo-
rated into usual care, this may well have blunted the ef-
fect of the current intervention. In addition, a large
proportion of the participants was not compliant to the
intervention, especially with respect to withdrawal of
psychotropic drugs (FRIDs withdrawal failed for 48 %
[48]). Higher compliance rates might have led to
reduced falls and lower related healthcare costs, and
increased savings due to reduced medication costs
(mean reduction of €38 per participant in this study).
Furthermore, a less costly method of FRIDs withdrawal
could be accomplished by having the GP perform the
intervention. This approach has been shown to be suc-
cessful, but would require an initial training programme
for the GPs [59].
Until now, only one falls prevention trial reported
HRQoL as recommended by ProFaNE. This multifactor-
ial intervention trial reported no significant change in
EQ-5D and SF-12 scores between the intervention and
control group [18]. Four other trials used varying
methods to measure HRQoL. Two found no difference
in SF-36 score between the intervention and control
group [24, 25]. Another multifactorial falls prevention
trial, which used the 15D instrument, concluded that the
intervention produced positive effects in some dimen-
sions of HRQoL [27]. Still another trial used the World
Health Organization Quality of Life instrument (WHO-
QoL) and measured higher quality of life in an exercise
training intervention group of patients who had recently
fallen [26].
Except for a structured medication assessment, including
the withdrawal of FRIDs, both groups received identical
care. Furthermore, withdrawal of certain commonly pre-
scribed FRIDs such as benzodiazepines, antidepressants
Table 2 Baseline characteristics of the control and intervention
group
Control
n = 293
Intervention
n = 319
Demographics
Age (year) 76.4 ± 6.6 76.5 ± 7.2
Female gender 182 (62) 198 (62)
MMSE 27.0 ± 2.4 27.0 ± 2.3
BMI (m2/kg) 27.6 ± 4.7 27.6 ± 4.6
Fall risk factors
Charlson Comorbidity Index 1.9 ± 1.6 1.9 ± 1.6
Number of drugs 6.4 ± 3.3 6.3 ± 3.3
Number of FRIDs 3.9 ± 2.0 3.9 ± 2.1
History of recurrent falls 128 (44) 148 (46)
Smoking 37 (13) 34 (11)
Alcohol intake (≥3 units/day) 33 (11) 34 (11)
Functional status
Home care 69 (24) 82 (26)
Activities of Daily Living 0.80 ± 4.5 0.80 ± 3.3
Instrumental Activities of Daily Living 1.39 ± 5.4 1.37 ± 4.0
Continuous data are shown as mean values ± standard deviation, categorical
data as number with percentage
MMSE Mini-Mental State Examination, BMI Body Mass Index, FRID Fall-Risk
Increasing Drugs
Table 3 Mean costs per patient of the control and intervention
group during 12 months follow-up
Cost categories Control
(n = 272)
Intervention
(n = 308)
p-value
Intervention costs - 120† *
General Practitioner consult costs 29 20 *
Specialist consult costs 51 40
Emergency Department costs 12 10
Hospital stay costs 360 383
Home care costs 662 630
Physical therapy costs 290 218
Intermediate care facility costs 220 74
Nursing home costs 424 156
Rehabilitation center costs 229 708
Patient costs (travel costs) 3 2
Change in medication costs‡ −3 −38 *
Total costs 2285 2324
Data are given as mean values in euro (€).†Average;* < 0.05
‡ The change in medication costs was reported, since the main aim of the
intervention was to withdraw medication. The total costs of medication in
general is related to the health state and comorbidity at start of the
intervention and were highly driven by some outliers
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and opiates [38], could have resulted in lower quality of life
scores in the intervention group. Nevertheless, in this study
the withdrawal of FRIDs did not lower the HRQoL.
Remarkably, in the secondary analysis comparing the par-
ticipants without a fall during follow-up, the intervention
group had less decline in the SF-12 PCS score than the
control group. The fact that the intervention did not lower
the HRQoL and possibly even improved it, is on its own an
important outcome. The participants who fell during
follow-up had significantly lower EQ-5D and SF-12 PCS
scores at baseline. This is in a group of community-
dwelling older persons who all visited the ED due to a fall;
Table 4 Quality of life scores of the control and intervention group at baseline and 12 months follow-up, and the change over
12 months
Group N† Baseline Follow-up p-values* Change p-values**
EQ-5D utility score Control 263 0.78 ± 0.22 0.74 ± 0.25 0.01 −0.04 ± 0.22 0.02
Intervention 285 0.74 ± 0.26 0.75 ± 0.26 0.75 0.01 ± 0.24
SF-12 PCS score Control 258 46.2 ± 9.9 42.2 ± 11.6 <0.01 −3.9 ± 8.5 0.08
Intervention 283 45.6 ± 9.5 43.0 ± 10.7 <0.01 −2.6 ± 8.5
SF-12 MCS score Control 258 53.2 ± 9.0 52.5 ± 9.2 0.28 −0.7 ± 9.7 0.90
Intervention 283 53.3 ± 9.5 52.5 ± 9.0 0.20 −0.8 ± 9.7
Data are given as mean values ± standard deviation
†9 and 23 participants in the control and intervention group declined or were unable to complete EQ-5D questionnaires after 12-months follow-up, an additional
5 and 2 participants in the control and intervention group had incomplete SF-12 questionnaires after 12-months follow-up
*Wilcoxon Signed Rank test (comparing baseline and follow-up)
**Two-way ANOVA of the change over 12 months
Fig. 2 Prevalence of problems on the five dimensions of the EQ-5D in the control and intervention groups at baseline and 12 months follow-up.
Nine and 23 participants in the control and intervention group declined or were unable to complete EQ-5D questionnaires after 12-months
follow-up. *p-values were measured with the McNemar test
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those who fell during follow-up had lower quality of life
scores ahead of the recurrent fall. This finding has not been
reported before and can be used as a tool in further
research and investigations to identify those older fallers
most at risk of a further fall.
An important finding in this study was the lower base-
line EQ-5D utility score in the intervention group com-
pared to the control group, regardless of similar baseline
characteristics including age, gender, and number of
comorbidities. This cannot be a result of differences in
reporting procedures, as the method and timing of
HRQoL questionnaire completion were identical for the
control and intervention groups. A possible explanation
for the lower baseline EQ-5D utility score in the inter-
vention group could be the presence of more severe
injuries in the intervention group at baseline. However,
the injuries sustained by the participants at baseline did
not differ significantly between the two groups. Overall,
42 % of participants sustained a fracture at baseline,
43 % in the control group and 40 % in the intervention
group. Furthermore, 3 % of participants in the control
and in the intervention groups sustained a traumatic
brain injury at baseline.
Some limitations should be taken into account when
interpreting results of this study.
First, recruiting participants proved challenging, the
recruitment-period lasted four years despite enrolling at
six hospitals. Reasons for refusing to participate have
been reported previously, i.e., mobility impairment and
lack of transportation options [60]. Second, the dropout
of 32 participants during the 12 months follow-up might
be due to the selected study population, which had a
high risk of falling. These participants had often mobility
impairments and other multiple morbidity which may
have resulted in a refusal to continue participating in the
study and visit the outpatient research clinic after
12 months follow-up. Thus the most at-risk and frail
participants may have been excluded from the analysis.
More individuals were excluded from the intervention
group because of poorer HRQoL (23 of the 32 dropouts)
which may have influenced, at least in part, the better
outcomes in the intervention group.
However, the randomization would have equally divided
these patients across the intervention and control group.
Third, the SF-12 has been evaluated for use in large
group comparisons, this may not be justified for the
secondary analyses comparing participants with and
without a fall during follow-up [44]. Fourth,
randomization did not seem to balance the groups
on some important variables (e.g., rehabilitation,
nursing home care), which can be attributed to the
relatively small sample size of the study.
Conclusions
In the present study withdrawal of FRID’s in older
persons who visited an Emergency Department due
to a fall, did not lead to reduction of total health-
care costs. The mean cost of the FRIDs intervention
was €120 per patient, but this did not result in
significant cost reductions in total healthcare costs.
However, the withdrawal of FRIDs reduced medica-
tion costs with a mean of €38 per participant which
in combination with less decline in HRQoL is an
important result.
Table 5 Quality of life scores of the participants with and without a fall during follow-up
Fall Group N Baseline Follow-up p-values* Change p-values**
EQ-5D utility score Control 87 0.71 ± 0.25 0.64 ± 0.28 0.01 −0.07 ± 0.29 0.13
Intervention 101 0.68 ± 0.29 0.67 ± 0.28 0.70 −0.01 ± 0.27
SF-12 PCS score Control 88 44.0 ± 10.4 39.3 ± 13.1 <0.01 −4.7 ± 9.8 0.72
Intervention 107 44.8 ± 9.5 40.7 ± 11.2 <0.01 −4.2 ± 10.2
SF-12 MCS score Control 88 53.6 ± 9.1 51.6 ± 10.5 0.14 −1.9 ± 10.8 0.56
Intervention 107 52.4 ± 10.6 51.7 ± 9.2 0.25 −1.0 ± 11.1
No fall Group N Baseline Follow-up p-values* Change p-values**
EQ-5D utility score Control 169 0.81 ± 0.19 0.80 ± 0.22 0.27 −0.02 ± 0.16 0.08
Intervention 180 0.77 ± 0.24 0.80 ± 0.23 0.44 0.02 ± 0.16
SF-12 PCS score Control 172 47.3 ± 9.6 43.9 ± 10.4 <0.01 −3.5 ± 7.8 0.01
Intervention 178 46.1 ± 9.6 44.5 ± 10.2 <0.01 −1.5 ± 7.1
SF-12 MCS score Control 172 53.1 ± 9.0 53.0 ± 8.5 0.76 −0.1 ± 9.2 0.46
Intervention 178 53.9 ± 8.8 53.0 ± 8.9 0.40 −0.9 ± 8.8
C control, I intervention. Data are given as mean values ± standard deviation
*Wilcoxon Signed Rank test
**Two-way ANOVA
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Additional file 1: Improvefall study patient questionnaire. Patients
included in the Improvefall studie received a patient outcome
questionnaire regarding medical history, quality of life and a fall risk
profile. (PDF 536 kb)
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